Laura Bessen Acquires 62,000 Shares of CCCC
Insider buying activity at CCCC as Laura Bessen and others purchase shares.
Key Points
- Laura Bessen bought 62,000 shares of CCCC on June 24, 2026, as part of recent insider buying activity.
- Shares of CCCC traded near $4.40 on Saturday, with various institutional investors adjusting their positions.
- Analysts from Evercore ISI and Barclays maintain a 'buy' rating with price targets of $12 and $7, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Laura Bessen made a notable move by purchasing 62,000 shares of CCCC on June 24, 2026. This insider buying activity is part of a broader trend among company insiders, suggesting a potential vote of confidence in the company's future.
Insider Buying and Selling at C4 Therapeutics, Inc.
On June 24, 2026, several insiders including Laura Bessen, Steven Hoerter, Stephen Fawell, Owen Hughes, and Donna Roy Grogan each bought 62,000 shares of CCCC. These transactions were not part of a pre-arranged trading plan, indicating a proactive decision to acquire shares. Kenneth Carl Anderson also bought 1,070 shares earlier in the month at $2.11 per share.
Other Institutional Activity in CCCC
Morgan Stanley increased its holdings by 90,738 shares, bringing its total to 9,072,400 shares valued at approximately $23.86 million. Vanguard Capital Management LLC opened a new position with 3,861,852 shares worth about $10.16 million. Meanwhile, Lynx1 Capital Management LP reduced its stake by 99,231 shares, ending with 6,998,902 shares valued at $18.41 million.
C4 Therapeutics, Inc. Stock Up 14.3%
Shares of CCCC traded near $4.40 on Saturday. The stock has experienced varied institutional interest, reflected in the recent insider buying activity. This price level offers a snapshot of current market sentiment as institutional investors adjust their positions.
$CCCC stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 1, 2026, Evercore ISI Group maintained its 'buy' rating for CCCC with a price target of $12. Barclays also maintained a 'buy' rating with a target of $7 on February 27, 2026. Overall, the consensus among analysts remains positive, with a strong buy recommendation and several firms reiterating their confidence in the stock's potential.
Bottom Line
Insider buying activity at CCCC, including purchases by Laura Bessen and other executives, suggests increased confidence in the company's prospects. It's important for investors to note that these insider transactions are reported after the fact and may not represent current holdings. Analyst ratings continue to reflect optimism, with multiple firms maintaining 'buy' recommendations and setting ambitious price targets.
Get C4 Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CCCC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.